In this week’s episode we will review a study exploring recurrent somatic deletions at chromosome 13q12.2 in acute lymphoblastic leukemia leading to upregulation of FLT3, examine how matriptase-2 plays a key role in suppressing hepatic hepcidin expression, and learn about the addition of daratumumab to lenalidomide, bortezomib, and dexamethasone as a quadruple therapy for transplant eligible patients with newly diagnosed multiple myeloma.